Flex Pharma Inc  

(Public, NASDAQ:FLKS)   Watch this stock  
Find more results for ELIZABETH HAHN´┐Ż
11.88
0.00 (0.00%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.69 - 12.04
52 week 6.48 - 17.60
Open 11.78
Vol / Avg. 0.00/117,948.00
Mkt cap 213.46M
P/E     -
Div/yield     -
EPS -2.12
Shares 17.97M
Beta     -
Inst. own 51%
Aug 3, 2016
Q2 2016 Flex Pharma Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 13, 2016
Flex Pharma Inc at Cantor Fitzgerald Healthcare Conference - Webcast
Jun 22, 2016
Flex Pharma Inc at ROTH Healthcare Day
Jun 21, 2016
Flex Pharma Inc at JMP Securities Life Sciences Conference
Jun 15, 2016
Flex Pharma Inc at Piper Jaffray Consumer Conference
Jun 9, 2016
Flex Pharma Inc at Jefferies Healthcare Conference - Webcast
May 4, 2016
Q1 2016 Flex Pharma Inc Earnings Release
May 4, 2016
Q1 2016 Flex Pharma Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -42.21% -44.60%
Return on average equity -43.63% -68.04%
Employees 31 -
CDP Score - -

Address

800 Boylston St Fl 24
BOSTON, MA 02199-8119
United States - Map
+1-617-8741821 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

Officers and directors

Christoph H. Westphal M.D. Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
Marina Hahn President, Consumer
Age: 57
Bio & Compensation  - Reuters
Kathie Lindemann Chief Operating Officer
Age: 54
Bio & Compensation  - Reuters
John McCabe Vice President - Finance, Treasurer
Age: 45
Bio & Compensation  - Reuters
Jennifer Cermak Ph.D. Vice President - Research & Development
Age: 42
Bio & Compensation  - Reuters
Robert Hadfield Ph.D. General Counsel, Secretary
Age: 37
Bio & Compensation  - Reuters
Elizabeth Woo M.D. Ph.D. Senior Vice President, Investor Relations and Corporate Communications
Age: 49
Bio & Compensation  - Reuters
Thomas C. Wessel M.D., Ph.D. Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Jeffrey D. Capello Director
Age: 50
Bio & Compensation  - Reuters
Roderick Mackinnon M.D Director
Age: 59
Bio & Compensation  - Reuters